RNS Number : 9338X
Hikma Pharmaceuticals Plc
28 April 2023
 

 

Hikma Pharmaceuticals PLC

Results of 2023 Annual General Meeting

LONDON, 28 April 2023 Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) announces its Annual General Meeting ("AGM"), held at Sofitel London St James, 6 Waterloo Place, London SW1Y 4AN and virtually on 28 April 2023 commenced at 11 am. All the proposed resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 20 were passed as ordinary resolutions and Resolutions and 21 to 24 were passed as special resolutions.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the FCA's Electronic Submission System and will be available from the National Storage Mechanism.

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 16 March 2023) is set out below. The number of Ordinary Shares in issue on 27 April 2023 was 233,821,373.  There were 12,833,233 Ordinary Shares held in treasury, which are not counted in the voting capital of the Company which, therefore, was 220,988,140.

Resolution

Votes For

%

Votes Against

%

Total Cast

Withheld

1. To receive the 2022 report and accounts

173,404,465

99.99

18,525

0.01

173,422,990

1,486,671

2. To approve a final dividend of 37 cents per share

174,904,572

100.00

3,407

0.00

174,907,979

1,682

3. To re-appoint PricewaterhouseCoopers LLP as Auditor

173,901,259

99.43

1,004,451

0.57

174,905,710

3,951

4. To authorise the Audit Committee to determine the remuneration of the Auditor

174,902,468

100.00

4,247

0.00

174,906,715

2,946

5. To elect Laura Balan as a Director of the Company

174,560,635

99.80

345,653

0.20

174,906,288

3,373

6. To elect Victoria Hull as a Director

172,985,379

98.90

1,920,959

1.10

174,906,338

3,322

7. To elect Dr Deneen Vojta as a Director

174,145,610

99.57

759,059

0.43

174,904,669

4,992

8. To re-elect Said Darwazah as a Director

167,417,879

95.79

7,363,833

4.21

174,781,712

127,949

9. To re-elect Mazen Darwazah as a Director

166,197,026

95.09

8,584,687

4.91

174,781,713

127,948

10. To re-elect Patrick Butler as a Director

169,789,166

97.08

5,115,966

2.92

174,905,132

4,529

11.To re-elect Ali Al-Husry as a Director

173,667,423

99.36

1,114,623

0.64

174,782,046

127,615

12. To re-elect John Castellani as a Director

174,135,021

99.56

770,111

0.44

174,905,132

4,529

13. To re-elect Nina Henderson as a Director

172,945,073

98.88

1,961,390

1.12

174,906,463

3,198

14. To re-elect Cynthia Flowers as a Director

174,560,963

99.80

345,325

0.20

174,906,288

3,373

15. To re-elect Douglas Hurt as a Director

174,135,291

99.56

769,811

0.44

174,905,102

4,559

16. To receive and approve the annual report on Remuneration

169,944,824

97.16

4,959,681

2.84

174,904,505

5,145

17. To approve the Directors' Remuneration Policy

171,820,411

98.24

3,085,011

1.76

174,905,422

4,239

18. To authorise the Directors to allot shares and grant rights to subscribe for shares

169,738,766

97.05

5,168,220

2.95

174,906,986

2,674

19. To approve the Long-Term Incentive Plan 2023

172,742,090

98.76

2,164,458

1.24

174,906,548

3,113

20. To approve the Deferred Bonus Plan 2023

173,885,322

99.42

1,021,749

0.58

174,907,071

2,590

21. To authorise the disapplication of pre-emption rights (General)

166,689,167

95.30

8,217,162

4.70

174,906,329

3,331

22. To authorise the disapplication of pre-emption rights (Acquisition or Capital Investment)

159,504,839

91.19

15,401,490

8.81

174,906,329

3,331

23. To authorise the Company to purchase Ordinary Shares

173,797,944

99.42

1,018,079

0.58

174,816,023

93,638

24. To authorise the Company to hold general meetings on not less than 14 clear days' notice

169,319,647

96.81

5,588,186

3.19

174,907,833

1,828

 

 

Senior Independent Director

 

At the conclusion of the AGM, as reported in our 2022 Annual Report, Patrick Butler stepped down as Senior Independent Director, Chair of the Nomination and Governance Committee and as a member of the Audit Committee and Remuneration Committee. Patrick Butler will remain on the Board as a non-independent Non-Executive Director for one further year, stepping down no later than the 2024 AGM. Victoria Hull was appointed as Senior Independent Director and Chair of the Nomination and Governance Committee.

Declaration of final dividend

The dividend of 37 cents per share will be paid on 5 May 2023 to shareholders on the register on 24 March 2023. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.2532 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa $1 to 0.71JD.

 

 

- ENDS -

Enquiries:

 

Hikma Pharmaceuticals PLC

 

Hussein Arkhagha

Chief Counsel and Company Secretary

 

+44 20 7399 2670

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGSEDFLAEDSEEL